BCG015
/ Biocytogen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
BCG015:A first-in-class antibody-drug conjugate targeting TM4SF5 for the treatment of hepatocellular carcinoma
(AACR 2026)
- "BCG015 represents a novel, first-in-class ADC targeting TM4SF5 with strong preclinical efficacy. These findings highlight its potential as a promising therapeutic option for HCC patients with TM4SF5 expression, addressing a significant unmet need in liver cancer treatment."
ADC • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • TM4SF5
1 to 1
Of
1
Go to page
1